- Home
- ILPT vs AVIR Comparison
ILPT vs AVIR Comparison
Compare ILPT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILPT
- AVIR
- Stock Information
- Founded
- ILPT 2017
- AVIR 2012
- Country
- ILPT United States
- AVIR United States
- Employees
- ILPT N/A
- AVIR N/A
- Industry
- ILPT Real Estate Investment Trusts
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- ILPT Real Estate
- AVIR Health Care
- Exchange
- ILPT Nasdaq
- AVIR Nasdaq
- Market Cap
- ILPT 315.4M
- AVIR 290.4M
- IPO Year
- ILPT 2018
- AVIR 2020
- Fundamental
- Price
- ILPT $4.61
- AVIR $3.46
- Analyst Decision
- ILPT Buy
- AVIR Hold
- Analyst Count
- ILPT 2
- AVIR 1
- Target Price
- ILPT $10.00
- AVIR $6.88
- AVG Volume (30 Days)
- ILPT 386.8K
- AVIR 254.4K
- Earning Date
- ILPT 10-29-2024
- AVIR 11-06-2024
- Dividend Yield
- ILPT 0.87%
- AVIR N/A
- EPS Growth
- ILPT N/A
- AVIR N/A
- EPS
- ILPT N/A
- AVIR N/A
- Revenue
- ILPT $441,893,000.00
- AVIR N/A
- Revenue This Year
- ILPT N/A
- AVIR N/A
- Revenue Next Year
- ILPT $6.87
- AVIR N/A
- P/E Ratio
- ILPT N/A
- AVIR N/A
- Revenue Growth
- ILPT 3.28
- AVIR N/A
- 52 Week Low
- ILPT $2.22
- AVIR $2.77
- 52 Week High
- ILPT $5.45
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- ILPT 38.92
- AVIR 40.35
- Support Level
- ILPT $4.52
- AVIR $3.30
- Resistance Level
- ILPT $4.97
- AVIR $3.41
- Average True Range (ATR)
- ILPT 0.16
- AVIR 0.15
- MACD
- ILPT -0.05
- AVIR -0.03
- Stochastic Oscillator
- ILPT 13.24
- AVIR 11.18
About ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).